Alpine Immune Sciences Inc (NASDAQ:ALPN) Is Focusing On INDs For ALPN-101 To Cure Autoimmune/Inflammatory Conditions
Alpine Immune Sciences Inc (NASDAQ:ALPN) recently announced its corporate update and financial results for the Q1 ended March 31, 2018. The company, which focuses on identifying and creating innovative, protein-based immunotherapies that target the immune synapse for treatment of cancer and other related medical conditions, is highly encouraged by its promising preclinical results that indicate a potential to come up with better approaches to tackle cancer and other diseases.
The company is currently focusing on its lead programs and it’s tracking its INDs for ALPN-101 for treatment of autoimmune/inflammatory conditions. Recently, Alpine presented its preclinical data for ALPN-202 program during the 2018 American Association for Cancer Research Annual Meeting.
The results indicate that molecules found in ALPN-2-2 program are able to tackle both PD-L1 and CTLA-4 and at the same time, offers the presence of a CD28 costimulatory signal. Hence, the immunotherapies are largely capable of eliminating various types of tumors.
The Company Appoints New CEO
Last month, Alpine appointed Chris Peetz to the firm’s Board of Directors as the CEO of Flashlight Therapeutics. Mr. Peetz brings on board wide experience in life sciences. He had worked previously as the CFO and Head of Corporate Development at Tobira Therapeutics and other key firms in the industry.
Mr. Peetz has a strong record of both strategic and financial achievements that will advance the development of two lead programs, ALPN-101 for autoimmune/inflammatory diseases and its ALPN-202 for immune-oncology indicates for the company.
The appointment of Mr. Peetz comes at the time when Alpine is expected to make a major impact by developing leading therapies for the treatment of complicated conditions such as cancer and others.
The Company Main Focus
Alpine is focused on developing new protein-based immunotherapies using its variant Ig Domain (vlgD) technology. The company has also developed a unique Transmembrane Immunomodulatory Protein (TIP) technology that enhances engineering of cellular therapies.
Alpine expects to have a cash fund for its future operations for the period 2018-2020 particularly for its clinical advancement of ALPN-101 for patients with autoimmune/inflammatory conditions, and ALPN-202 for cancer patients.
However, in the recent past, the company’s sales revenues have been falling with a negative year-on-year growth rate. According to a consensus of the most influential biotechnology analysts, the firm’s revenue level is approximated to fall further by negative 99.96% by 2021. With the continuous decline of the firm’s financial performance, it’s difficult to sustain positive earnings.